Here is a **comprehensive and detailed guideline** on the **evaluation and management of hyperkalemia**, based on the latest evidence and recommendations from:

* **American Heart Association (AHA)**
* **KDIGO (Kidney Disease: Improving Global Outcomes)**
* **European Resuscitation Council (ERC)**
* **American Society of Nephrology (ASN)**
* **Endocrine Society**
* Major 2023–2024 reviews in NEJM and UpToDate

---

# 🔍 HYPERKALEMIA – CLINICAL GUIDELINES (2024–2025)

---

## 🧬 1. DEFINITION & PHYSIOLOGY

| Classification | Serum K⁺ (mmol/L) | Clinical Notes                              |
| -------------- | ----------------- | ------------------------------------------- |
| Normal         | 3.5 – 5.0         |                                             |
| Mild           | 5.1 – 5.9         | Often asymptomatic                          |
| Moderate       | 6.0 – 6.4         | Risk of ECG changes                         |
| Severe         | ≥6.5              | High risk of arrhythmias, medical emergency |

**Pseudohyperkalemia**:

* Occurs due to hemolysis, leukocytosis, thrombocytosis, prolonged tourniquet
* Always re-check with **plasma potassium** and a fresh sample

---

## ⚠️ 2. CLINICAL SIGNIFICANCE

**Cardiac**:

* Ventricular arrhythmias
* Asystole or cardiac arrest
* Potentiates digoxin toxicity

**Neuromuscular**:

* Muscle weakness → flaccid paralysis
* Respiratory muscle involvement in severe cases

---

## 🧪 3. EVALUATION OF HYPERKALEMIA

### A. Confirm True Hyperkalemia

* Rule out **pseudohyperkalemia**

  * Hemolyzed sample
  * High WBC/platelet counts

---

### B. History and Risk Factors

* **Renal failure (AKI or CKD)**
* **Drugs**:

  * RAAS inhibitors (ACEi, ARBs)
  * Potassium-sparing diuretics (spironolactone, amiloride)
  * NSAIDs
  * Heparin (↓ aldosterone)
  * Beta-blockers
  * Trimethoprim, cyclosporine, tacrolimus
* **K⁺ supplements**
* **Tissue breakdown**: rhabdomyolysis, hemolysis, tumor lysis syndrome
* **Acidosis**: diabetic ketoacidosis, lactic acidosis

---

### C. Laboratory Workup

| Test                       | Purpose                            |
| -------------------------- | ---------------------------------- |
| Serum electrolytes         | K⁺, Na⁺, Cl⁻, HCO₃⁻                |
| Renal function             | BUN, Creatinine, eGFR              |
| Arterial/venous blood gas  | To assess acidosis                 |
| Serum glucose              | To determine insulin need          |
| ECG                        | To detect cardiac toxicity         |
| Plasma aldosterone & renin | In chronic hyperkalemia evaluation |

---

## ⚡ 4. ECG CHANGES IN HYPERKALEMIA

| Potassium Level | ECG Findings                                 |
| --------------- | -------------------------------------------- |
| 5.5 – 6.5       | Peaked T waves (especially precordial leads) |
| 6.5 – 7.5       | Prolonged PR interval, flattened P waves     |
| 7.5 – 8.0       | Widened QRS, ST depression                   |
| >8.0            | Sine wave pattern, asystole, VF/VT           |

---

## ⚕️ 5. MANAGEMENT STRATEGY

### KEY GOALS:

1. **Stabilize the myocardium**
2. **Shift K⁺ intracellularly**
3. **Remove excess K⁺**
4. **Prevent recurrence**

---

## 🧭 TREATMENT ALGORITHM (BASED ON SEVERITY)

---

### **I. EMERGENCY MANAGEMENT** (K⁺ ≥6.5 or ECG changes)

#### A. **Stabilize Cardiac Membranes**

| Treatment                | Dose                              | Onset   | Duration                   |
| ------------------------ | --------------------------------- | ------- | -------------------------- |
| **IV Calcium Gluconate** | 10 mL of 10% over 5–10 min        | 1–3 min | 30–60 min                  |
| **IV Calcium Chloride**  | 5–10 mL of 10% (via central line) | Faster  | More potent than gluconate |

> Repeat in 5–10 min if ECG changes persist

---

#### B. **Shift Potassium into Cells**

| Treatment                      | Dose                                             | Notes                                     |
| ------------------------------ | ------------------------------------------------ | ----------------------------------------- |
| **Insulin + Dextrose**         | 10 units regular insulin IV + 25–50g Dextrose IV | Mainstay; monitor glucose                 |
| **Beta-2 agonist (Albuterol)** | 10–20 mg nebulized                               | Adjunctive; avoid in CAD                  |
| **Sodium Bicarbonate**         | 50–100 mEq IV over 5–10 min                      | Useful in metabolic acidosis; not routine |

> Onset: 15–30 min, Duration: 2–6 hours

---

#### C. **Remove Potassium from Body**

| Treatment                                     | Dose                                       | Notes                                                            |
| --------------------------------------------- | ------------------------------------------ | ---------------------------------------------------------------- |
| **Loop diuretics (Furosemide)**               | 20–40 mg IV                                | If patient is volume overloaded                                  |
| **Sodium polystyrene sulfonate (Kayexalate)** | 15–30 g PO/PR                              | Delayed action (4–6 hrs); GI side effects                        |
| **Patiromer (Veltassa)**                      | 8.4–25.2 g PO daily                        | Chronic use only; not emergency                                  |
| **Sodium zirconium cyclosilicate (Lokelma)**  | 10 g TID × 2 days                          | Rapid acting but not first-line in life-threatening hyperkalemia |
| **Hemodialysis**                              | Emergent in severe/refractory hyperkalemia | Most effective for ESRD/AKI                                      |

---

### **II. NON-EMERGENT / CHRONIC MANAGEMENT** (K⁺ 5.1–6.4 without ECG changes)

1. **Stop potassium-retaining medications**
2. **Educate on low-potassium diet** (see section below)
3. **Initiate potassium binders**:

   * Patiromer or SZC preferred over SPS
4. **Treat contributing conditions**:

   * Volume overload, acidosis, uncontrolled diabetes

---

## 🥗 6. LOW-POTASSIUM DIET RECOMMENDATIONS

| Food to Avoid           | Safer Alternatives      |
| ----------------------- | ----------------------- |
| Banana, orange, avocado | Apple, grapes, berries  |
| Potatoes, tomatoes      | Rice, pasta, cucumber   |
| Spinach, lentils        | Zucchini, cauliflower   |
| Coconut water           | Plain water, buttermilk |

> **Target dietary K⁺ <2–3 g/day** in patients with CKD or recurrent hyperkalemia

---

## 📉 7. MONITORING & FOLLOW-UP

| Parameter           | Frequency                                     |
| ------------------- | --------------------------------------------- |
| Serum K⁺            | q4–6 hours (acute), daily or weekly (chronic) |
| ECG                 | Continuous if K⁺ >6.5 or symptoms             |
| Renal function      | Baseline and ongoing                          |
| Blood glucose       | Every 1–2 hrs after insulin                   |
| Magnesium & calcium | Rule out concurrent disturbances              |

---

## 🧬 8. SPECIAL POPULATIONS

### CKD Patients:

* Avoid dual RAAS blockade
* Use binders (patiromer/SZC)
* Encourage nephrology referral for dietary counseling

### Diabetics:

* Increased risk from insulin deficiency and RAASi
* Monitor closely when adjusting insulin

### Heart Failure:

* Hyperkalemia limits RAAS inhibitor use
* Patiromer helps maintain ACEi/ARB/MRA therapy

---

## 🚫 9. DRUGS TO AVOID IN HYPERKALEMIA

* Spironolactone, eplerenone
* ACE inhibitors, ARBs
* NSAIDs
* Heparin
* Trimethoprim
* Succinylcholine (in trauma/burns)

---

## ✅ 10. SUMMARY CHECKLIST

☑ Confirm true hyperkalemia
☑ Identify cause (renal failure, drugs, acidosis)
☑ ECG and cardiac monitoring
☑ Give IV calcium for ECG changes
☑ Shift K⁺ with insulin/dextrose ± beta-agonists
☑ Eliminate K⁺ with diuretics, binders, or dialysis
☑ Educate on diet and avoid offending agents
☑ Monitor K⁺, glucose, and renal function closely

---

Would you like this entire guideline as a **downloadable PDF** or a **treatment flowchart for quick reference**?
